Trials / Completed
CompletedNCT00586963
Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis
How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to for two reasons: * To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. * To learn about the quality of life changes (good and bad) you may experience with this medication.
Detailed description
The plan is to have 50 people take part in this study at Mayo Clinic Rochester. This research study is looking at people who have a new condition called erosive reflux esophagitis. Esophagitis is defined as mucosal damage produced by the abnormal reflux of gastric contents into the esophagus. Acid reflux, over time, can wear away or erode the lining of your esophagus. This condition is called erosive esophagitis. The treating physician may start you on prescription strength acid reducing group of medications called Proton Pump Inhibitors (PPI). PPI medications can provide 24-hour relief from your painful heartburn symptoms and it can help you heal the erosions in the esophagus that acid reflux may cause.
Conditions
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-10-01
- Completion
- 2008-12-01
- First posted
- 2008-01-07
- Last updated
- 2010-08-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00586963. Inclusion in this directory is not an endorsement.